Each subject will return to the site for study visits 3, 7 and 28 days post-prime vaccination; 28 days after prime vaccination the boost vaccination will be administered and subjects will return 3, 7, 28 days after boost vaccination. A primary analysis will be carrying out on data collected up to this timepoints. Subjects will be followed up for safety and immunogenicity thereafter up to 180 days post-prime.